Blow For Novartis As England’s NICE Says No To Kisqali

 
• By Neena Brizmohun

Novartis is having a harder time than Eli Lilly at getting health technology assessment body NICE to agree to make its breast cancer CDK4/6 inhibitor in combination with fulvestrant available on the National Health Service.

Dr and UK Purse
NICE is not ready to recommend Kisqali's use on the NHS • Source: Shutterstock

More from Health Technology Assessment

More from Market Access